ONCOLOGY-BASED THERAPY


Lining up a fresh approach to how we measure the efficacy of oncology-based therapies


, senior manager of EMEA Oncology Communication and Public Affairs at Janssen, tells us how crucial it is to explore various end points when developing oncology-based therapies.


In your opinion, how have oncology-based trials changed over the last 12 months? The most notable changes to oncology-based trials over the past 12 months have been around how we engage patients and investigators, given the impact of COVID-19. Traditional methods of in-person consultations and monitoring are no longer feasible. As a result, we’ve had to rethink how we conduct clinical research and we have adopted virtual approaches to monitoring patients and meeting with investigators. While we may go back to a degree of in-person


consultation in the future, some of the lessons we’ve learned from the adjustments made during the pandemic may actually benefit future trials, making them more accessible and more patient-oriented. For example, at Janssen, we are actively exploring clinical studies that would allow for patient-outcome monitoring within their own environments. This might be using a digital device or another tool that patients are comfortable with, and which allows us to leverage remote monitoring in a way that is most convenient to patients.


 |


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50